Inmune Bio Inc (INMB) 13F Ownership Report (Q2 2026)

INMB ranks #4995 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

INMB is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

84 institutions disclose a position in INMB, but none treat it as a major bet — even Curated Wealth Partners LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Cliff Asness has added to its INMB position for two straight quarters, increasing it by $1.0M to reach $1.1M today.

BlackRock has trimmed its INMB position for two straight quarters, cutting it by $1.4M while still holding $507.9K.

INMB is up 0.6% today, but institutions show net selling of $1.1M this quarter — a divergence between today's price move and the underlying institutional flow.

INMB reported a net loss of $18.4M over the trailing twelve months.

• Not yet profitable — net loss of $18.4M over the trailing twelve months
• Revenue grew 257.1% year over year
• Net income improved year over year, from -$55.5M to -$18.4M
• Operating cash flow was negative, using $22.6M in cash
• Current ratio of 3.55x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.38x equity — within a conventional range